Indonesia • Dexa Medica


Ticagrelor coadministered with acetylsalicylic acid 75-100mg is indicated for the prevention of thrombotic events (cardiovascular death, myocardial infarction, and stroke) in patients with acute coronary syndromes (ACS) [unstable angina, non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI) including patients managed with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).


Ticagrelor 90 mg


3 blisters of 10 tablets

Dosage Forms


ATC Classification



Not Recommended
This item should not be used with alcohol.
This item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.
Consult Your Doctor
Safety of this item for use during pregnancy has not been established. Please consult your doctor.
Not Recommended
This item is not safe for use during lactation.


Up to 18 Years

The safety and efficacy of ticagrelor in children below the age of 18 years have not been established. No data are available.

18 Years Old and Above

Patients taking ticagrelor should also take a daily low maintenance dose of acetylsalicyclic acid 75-100 mg, unless specifically contraindicated. For acute coronary syndromes, ticagrelor treatment should be initiated with a single 180 mg loading dose (two tablets of 90 mg) and then continued at 90 mg twice daily.

Ticagrelor can be administered with or without food.

Elderly Patients

No dose adjustment is required in elderly.

Patients with Renal Impairment

No dose adjustment is necessary for patients with renal impairment. No information is available concerning treatment of patients on renal dialysis and therefore ticagrelor is not recommended in these patients.

Patients with Hepatic Impairment

Ticagrelor has not been studied in patients with severe hepatic impairment and its use in these patients is therefore contraindicated. Only limited information is available in patients with moderate hepatic impairment. Dose adjustment is not recommended, but ticagrelor should be used with caution. No dose adjustment is necessary for patients with mild hepatic impairment.